About FID-007

FID-007 is composed of paclitaxel encapsulated with a polyethyloxazoline polymer using our nanoencapsulation platform and our nano-drug delivery technology.

In Phase 1/1b clinical trials, FID-007 showed a manageable safety profile and demonstrated preliminary evidence of anti-tumor activity in heavily pre-treated patients across different tumor types. No high-grade neuropathy has been noted to date.

The target markets for FID-007 are large and well-established, including head and neck (H&N), pancreatic, breast, and non-small cell lung cancer (NSCLC). FID-007 is being evaluated in multiple clinical trials including “FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)” (Phase 2, ClinicalTrials.gov ID: NCT06332092, https://clinicaltrials.gov/study/NCT06332092), “FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer” (Phase 2, ClinicalTrials.gov ID: NCT06338657, https://clinicaltrials.gov/study/NCT06338657), and “FID-007 in Treating Participants With Advanced Solid Tumors” (Phase 1/1b, ClinicalTrials.gov ID: NCT03537690, https://clinicaltrials.gov/study/NCT03537690).